Ul­tragenyx bets up to $304M on an old No­var­tis drug for an ul­tra-rare bone dis­ease

Sev­er­al months af­ter get­ting its sec­ond FDA nod for Crysvi­ta, Ul­tragenyx is bet­ting up to $304 mil­lion on an­oth­er meta­bol­ic bone dis­ease can­di­date — and this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER